The Accelerating Clinical Trials in the EU (ACT EU) initiative aims to improve the conduct of clinical trials during public health emergencies in the European Union[1][2]. The COVID-19 pandemic and the monkey crisis have revealed the need to optimize processes for the rapid launch of multinational clinical trials in crisis situations[2]. ACT EU is working to develop guidelines and procedures that will enable accelerated registration and evaluation of clinical trials without lowering safety standards[3]. The aim is to strengthen coordination between Member States, regulatory authorities and ethics committees in order to reduce the times needed to approve and start studies[3]. The program also aims to improve safety monitoring during clinical trials through the creation of pharmacovigilance networks[2]. These measures are intended to contribute to the fact that patients in the EU are more quickly informed about new treatment options during health crises and to increase the competitiveness of the European research environment[4].